Rocket company exploring purchase of select Orbex assets

Orbex, a Forres-based orbital launch company employing 163 staff, has filed a notice of intention to appoint administrators after failing to secure required funding, though it will continue trading while options including asset sales are explored; it had been near first test launches of its Prime microlauncher and in December paused plans for a Sutherland spaceport while retaining the lease. Skyrora, which holds a UK domestic launch licence and has manufacturing/testing capability, is exploring purchase of select Orbex assets and said it could invest up to £10 million to keep technology and critical infrastructure under UK ownership; any deal remains subject to administrators, due diligence and legal processes.

Analysis

Market structure: A Skyrora purchase of select Orbex assets (talks imply up to £10m investment) is a consolidation that benefits Skyrora (sovereign launch positioning) and listed defense primes with UK exposure (e.g., BA.L, LMT) because it reduces domestic competition and increases strategic pricing power for UK-based launches (estimate a 5–15% premium for “sovereign” access). Losers are early-stage UK launch investors, Orbex equity/staff and small suppliers whose receivables/valuation will be written down; expect FTSE AIM aerospace constituents to see near-term mark-to-market stress.

Risk assessment: Tail risks include a government block on IP transfer or nationalization (high impact, low prob) or litigation/indemnity claims from delayed payloads costing >£20–50m. Time horizons: immediate (days) — employee/contract uncertainty and admin filings; short-term (30–90 days) — due diligence, administrator decisions; medium (6–18 months) — certification and launch schedule slippage. Hidden dependencies: customer insurance, spaceport lease terms (Sutherland), and supplier bonds that could trigger cross-defaults.

Trade implications: Direct plays — overweight Rocket Lab (RKLB) as an immediate alternative for microlaunch demand, and selective longs in BA.L or LMT for sovereign defense exposure. Use option structures: buy RKLB 3–6 month call spreads (25–40% OTM) to express asymmetric upside if payloads reroute; hedge by buying 3–6 month put spreads on an FTSE AIM aerospace basket. Timing: enter after 10–30 days when administrators publish asset-sale signals, target 6–12 month holding period.

Contrarian angles: Consensus understates Orbex IP value — acquisition ≤£10m could have replacement-cost upside >3–5x if tooling/engines are intact, creating a rapid capability boost for Skyrora. Conversely, technical/regulatory risk is underpriced: a failed integration could widen UK launch insurance costs and benefit non-UK providers (Rocket Lab) for multiple years. Historical parallel: post-crisis consolidation in Europe’s launch sector created 3–7 year windows of outsized revenue for surviving incumbents.

Key Decisions for Investors

• Establish a 1–2% portfolio overweight in Rocket Lab (RKLB) via equity or a 3–6 month call spread 25–40% OTM to capture potential re-routing of microlaunch demand; size to limit drawdown to ~2% of NAV and re-evaluate after administrators announce asset-sale outcomes (target review in 30 days).
• Add a 1–2% sovereign-defense hedge by initiating long exposure to BAE Systems (LSE: BA.L) or Lockheed Martin (NYSE: LMT) as beneficiaries of UK sovereign launch consolidation; trim if UK government explicitly nationalizes assets or awards large subsidies (trigger: announcement within 60 days).
• Establish a 0.5–1% tactical short or buy puts on a FTSE AIM/Aerospace small-cap basket (or individual names with >50% revenue tied to Orbex) to capture widening credit/valuation stress over the next 30–90 days; close within 6 months or on clear administrator resolution.
• Reserve a £5–10m private-equity watchlist allocation to bid on Orbex assets if they reach fire-sale pricing (≤£10m); prepare technical/legal diligence checklist (IP chain, export controls, insurance claims) and have term sheet ready within 30–60 days to move quickly.
• Monitor three specific catalysts: administrator sale notice (expected within 30–90 days), UK government statement on sovereign launch policy/subsidy (within 60 days), and Orbex customer manifests/insurance claim notices (within 14–45 days); act decisively when two of three confirm a long-term shift.